Shortcut Navigation:

Breast Cancer News

In this section, access cutting-edge breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.

MARIANNE Trial Shows T-DM1 Works About As Well As Standard First Treatment for HER2-Positive Metastatic Breast Cancer

At the end of 2014, the pharmaceutical company Genentech announced results from the phase III MARIANNE trial. These results show that T-DM1, with or without pertuzumab, works about as well as, but not significantly better than, the standard treatment for people newly diagnosed with HER2-positive metastatic breast cancer. Both T-DM1 and pertuzumab are sold by Genentech. The final results of MARIANNE will be presented at a future medical meeting and are not yet published in a medical journal.

Most Who Use Free Clinics for Breast Care Need More Information

Despite the importance for free clinics to promote breast health education to populations of women who may not get routine screenings or schedule regular check-ups, a recent study conducted at one such free clinic in the Intermountain West found that breast health information was limited. This was especially true among Spanish speakers and non-U.S. citizen English speakers.

Blocking Ovarian Function Benefits Some Young Women

The largest study of long-term breast cancer treatment using methods to stop estrogen production in premenopausal women with hormone receptor-positive disease has found what one of its authors calls “practice-changing” results for certain women.

Most Women Delay Breast Reconstruction

Researchers found that immediate breast reconstruction, surgery to rebuild the breast done at the same time as mastectomy, is most likely to be used by young women in big cities who have private insurance and few chronic medical problems. Overall though, more women do NOT have their breasts rebuilt at that time.

Updates from San Antonio Breast Cancer Symposium

Highlights from the annual San Antonio Breast Cancer Symposium held December 9-13, 2014 including presentation of results from a new survey conducted by Living Beyond Breast Cancer on the psychosocial needs of women with triple-negative breast cancer. 

Electroacupuncture May Ease Hormonal Therapy Side Effects Such As Fatigue, Anxiety and Depression

A recent small study found that electroacupuncture significantly lessened fatigue, anxiety and depression among postmenopausal woman with aromatase inhibitor-related joint pain.

Study: Severe Side Effects Uncommon After Taking T-DM1

After looking at information from seven studies involving T-DM1 (Kadcyla), researchers found that severe side effects were uncommon. If they did occur, they were usually manageable.

Large Study Confirms Trastuzumab More Effective Than Lapatinib

At the European Society for Medical Oncology 2014 Congress, in Madrid, in late September, Researchers presented expanded results from the ALTTO trial. These results show trastuzumab alone is more effective than lapatinib alone for early-stage, HER2-positive breast cancer.

Zoledronic Acid May Prevent Cancer Return in Postmenopausal Women With Early-Stage Breast Cancer

Researchers with the AZURE trial found that giving the bone strengthening medicine zoledronic acid (Zometa) after standard treatment for early-stage breast cancer lessened the chance of cancer returning in postmenopausal women. It also lessened the chance of bone problems in all women.

PET/CT Scans May Clarify Staging for Certain Young Women

A study of young women diagnosed with stage I-III breast cancer using traditional staging methods found that later PET/CT scans changed 21 percent of those diagnoses to stage III or IV.

Close
close